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Background
Parenteral nutrition (PN) serves as a critical therapy for patients in conditions where oral 
ingestion is not adequate. In spite of its usefulness, there are also many possible com-
plications, such as catheter-related bloodstream infection (Hvas et  al. 2014), impaired 
glucose tolerance (Beltrand et al. 2007), and parenteral nutrition-associated liver disease 
(Nandivada et al. 2013). In addition, long-term PN administration can induce intestinal 
atrophy; the reduction of the mucosal barrier may mediate bacterial translocation (BT), 
in which the intestinal bacteria and/or their toxic products invade the bloodstream and 
induce production of inflammatory cytokines, subsequently leading to sepsis and multi-
ple organ failure (Hatakeyama and Matsuda 2014; Li et al. 1999; Sun et al. 2006).
Abstract 
Long-term parenteral nutrition (PN) can induce intestinal atrophy, leading to a loss of 
epithelial integrity in the small intestines. This change may alter the intestinal perme-
ability of vancomycin (VCM), a non-absorbable antibiotic. The aim of the present study 
was to investigate the effect of PN on the pharmacokinetics of VCM in rats. VCM was 
intravenously (5 mg/kg) or intraduodenally (20 mg/kg) administered to control and PN 
rats, which were prepared by administration of PN for 9 days. After intravenous admin-
istration, there were no significant differences in any of the VCM pharmacokinetic 
parameters between the control and PN rats. However, after intraduodenal adminis-
tration, the maximum concentration and area under the plasma concentration–time 
curve of VCM in PN rats was approximately 2.4- and 2.6-fold higher, respectively, than 
in the control rats; the calculated bioavailability was approximately 0.5 and 1.3 % in 
control and PN rats, respectively. These results indicated that PN administration did not 
affect VCM disposition, but enhanced VCM absorption; however, the enhanced oral 
VCM bioavailability was statistically, not clinically, significant. Therefore, while long-term 
PN administration may play a role in the enhancement of VCM bioavailability, this effect 
may be negligible without any complications.
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Selective decontamination of the digestive tract (SDD) prophylaxis of BT, which pre-
vents the overgrowth of pathogens by enteral co-administration of non-absorbable anti-
biotics, such as colistin, tobramycin, amphotericin B, and vancomycin (VCM) (Benus 
et al. 2010; Cerdá et al. 2007; Roos et al. 2011) has been previously reported. It has been 
shown that any absorption of the non-absorbable antibiotic in the SDD regimen can 
be considered negligible under “normal conditions”; however, significant absorption of 
tobramycin was reported in critically ill patients (Oudemans-van Straaten et al. 2011), as 
was VCM in patients with chemotherapy-associated and/or Clostridium difficile colitis 
(Aradhyula et al. 2006; Bergeron and Boucher 1994). In addition, we previously reported 
the enhanced intestinal permeability of a hydrophilic dye, phenolsulfonphthalein, in PN-
induced intestinal atrophy (Fukushima et al. 2015). On the basis of these findings, there 
is potential to enhance the absorption of typically non-absorbable antibiotics in patients 
with PN-induced intestinal atrophy. It is well known that trough concentrations of VCM 
are associated with its nephrotoxicity (Elyasi et al. 2012) and that the rapid infusion of 
VCM induces red man syndrome (Healy et al. 1990). Generally, the absorption via pas-
sive diffusion of a hydrophilic drug is rapid. Therefore, there are concerns about side 
effects caused by the systemic exposure after enteral administration of VCM.
The aim of the present study was to investigate the impact of PN-induced intestinal 
atrophy on the absorption of VCM and to assess its clinical significance. Based on the 
usage of VCM in SDD regimen, VCM was administered intraduodenally to rats admin-




An injectable formulation of vancomycin (VCM) hydrochloride was purchased from 
Shionogi Co., Ltd., (Osaka, Japan). PNTWIN® No.3 and VITAJECT® were purchased 
from Ajinomoto Pharmaceuticals Co., Ltd. (Tokyo, Japan) and Terumo Co., Ltd. (Tokyo, 
Japan), respectively. Ampicillin and bupivacaine were obtained from Meiji Seika Pharma 
Co., Ltd. (Tokyo, Japan) and AstraZeneca PLC (London, UK), respectively. All other rea-
gents were of analytical grade and were used without further purification. Male Wistar 
rat (weighing 250 ±  10  g, 10-weeks old) were purchased from Nippon SLC Co., Ltd. 
(Hamamatsu, Japan). All animal experiments in the present study were approved by 
the Animal Experimentation Committee of Kobe Gakuin University (approval number: 
A14-31). Rats had free access to food and water and were acclimated in a temperature-
controlled facility with a 12 h light/dark cycle for at least 3 days before use.
Preparation of PN‑administered rats and laboratory tests
Parenteral nutrition-administered rats (PN rats) were prepared by the same method in 
our previous report (Fukushima et al. 2015) with only a change in the duration of PN 
administration; the preparation scheme of the PN rats are shown in Scheme 1. Briefly, 
3 days before the start of PN administration, cardiac catheterization was performed via 
the right jugular vein with a polyurethane catheter (0.6-mm ID, 0.9-mm OD, Primetech 
Co., Tokyo, Japan) in rats anesthetized with sodium pentobarbital, and given ampicil-
lin for prevention of infection and local bupivacaine for pain relief. The cannulated rats 
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were housed individually in cages with free access to food and water, and received saline 
at a rate of 0.1  mL/h for 3  days via the catheter with a syringe pump (ISIS Co., Ltd., 
Osaka, Japan), and daily ampicillin (2 mg/kg, 2-min infusion) for recovery from surgery. 
For PN administration, infusion of PN solution was started at a rate of 1.25 mL/h for 
2 days under fasting and water-deprived conditions; PN solution consisting of glucose, 
amino acids, electrolytes, and vitamins (approximately 0.97 kcal/mL) was prepared by 
mixing PNTWIN No. 3 with VITAJECT (Fukushima et  al. 2015). Subsequently, PN 
administration was performed at a rate of 2.5 mL/h (viz., 60 mL/day, 58 kcal/day) for 
7 days; likewise, the sham operated rats (control rats) underwent the same regimen with 
saline and allowed free access to food throughout the treatment. All rats were fasted 
overnight before the VCM pharmacokinetic study, and blood samples for laboratory 
testing were taken just before VCM administration; total protein (TP), serum albumin 
level (Alb), total cholesterol (T-Cho), triglyceride (TG), aspartate transaminase (AST), 
alanine transaminase (ALT), blood urea nitrogen (BUN), and serum creatinine (CRE) 
were measured by a commercial laboratory, Oriental Yeast Co., Ltd. (Tokyo, Japan).
Intravenous and intraduodenal administration of VCM
The fasted control and PN rats were allocated to two groups (n =  4/group) based on 
the administration route: intravenous and intraduodenal VCM administration. In the 
intravenous administration study, rats were anesthetized with sodium pentobarbital 
(50 mg/kg), and the VCM saline solution (2.5 mg/mL) was bolus injected into the left 
femoral vein (5 mg/kg). Blood samples were taken 5, 15, 30, 45, 60, 90, 120, 180, 240, and 
360 min after administration, and were centrifuged at 12,000 rpm for 15 min to collect 
the plasma fraction. In the intraduodenal administration study, the abdominal cavity was 
opened in anesthetized rats and the stomach was exposed. A small incision was made 
on the lesser curvature of the stomach, and the VCM saline solution (10 mg/mL) was 
administered through the incision and the pylorus into the duodenum (20 mg/kg) using 
a sterilized oral feeding needle. After administration, the incision was closed with a tis-
sue adhesive and the pylorus was ligated. Blood samples were taken 5, 15, 30, 60, 90, 120, 
180, 240, 300, and 360 min after administration, and plasma samples were collected by 
centrifugation. The collected plasma samples in both studies were immediately frozen at 
−80 °C until analysis.
Scheme 1 PN regimen
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VCM assay
The VCM assay was performed by a previously reported liquid chromatography/tandem 
mass spectrometry (LC/MS/MS) method (Shibata et al. 2003) with some modifications; 
briefly, a 100 µL plasma sample was added to 60 µL of 30 % trifluoroacetic acid to pre-
cipitate protein. After vortexing and centrifugation at 12,000 rpm for 15 min, the super-
natant was diluted in 340 µL of distilled water and was passed through a filter, and 10 µL 
of the filtrate was injected into a Quattro Ultima LC/MS/MS system with a 2690 Sepa-
ration Module (Waters Co, MA, UK). VCM separation was performed with a QUICK-
SORB ODS column (i.d. 2.1 mm × 100 mm, 3 µm, Chemco Scientific Co., Ltd., Osaka, 
Japan), and the elution was carried out isocratically at a flow rate of 0.2 mL/min with 
the degassed mobile phase, acetonitrile: 0.1  % acetic acetate (2:8). Mass spectrometry 
was conducted with electrospray ionization in positive mode (ESI+) under the follow-
ing conditions: source temperature, 130 °C; cone voltage, 35 V; capillary voltage, 4.0 kV. 
VCM intensity was monitored by multiple reaction monitoring (MRM) with 18 eV of 
collision energy for the VCM transition (725–144 m/z). VCM concentration was quanti-
fied by calculating peak area against calibrated samples. The lower limit of quantitation 
for VCM was <0.005 µg/mL.
Pharmacokinetic analysis
A one- or two-compartment model with first-order absorption process was applied 
to the plasma concentration profiles of VCM; on the basis of the Akaike’s Information 
Criteria (AIC), the latter model was selected in the present study. All pharmacokinetic 
analyses were performed using WinNonlin® Version 6.3 (Pharsight, Mountain View, 
CA). The structural parameters, including the absorption rate constant (ka), distribu-
tion volume of the central compartment (Vc), distribution volume of the peripheral com-
partment (Vp), total body clearance (CLtot), and distribution clearance (CLD2), and the 
secondary parameters including the maximum concentration (Cmax), time to maximum 
concentration (Tmax), distribution half-life (t1/2α), elimination half-life (t1/2β), and the 
area under the plasma concentration–time curve (AUC) were calculated. The bioavail-
ability (F) was calculated using the following equation: 
where Dose represents the administered dosage.
Statistical analyses
All values are represented by the mean ± standard error (SE). Statistical differences of 
the means were assumed to be significant when p < 0.05 by the Mann–Whitney U test.
Results
Body weight and laboratory test results of the control and PN rats are shown in Addi-
tional file 1: Table S1. Body weight, TP, and Alb were slightly, but significantly, decreased 
in PN rats (approximately 88, 82 and 86 % of control, respectively), and TG levels in PN 
rats were markedly decreased, approximately 28 % of control. The plasma concentration 
profiles of VCM after intravenous and intraduodenal administration are shown in Figs. 1 
and 2, respectively. After intravenous administration, the plasma concentration profiles 
F = (AUCintraduodenal/Doseintraduodenal)/(AUCintravenous/Doseintravenous),
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of both control and PN rats were similar, and declined in a biphasic manner; after intra-
duodenal administration, the concentration of VCM in control and PN rats reached a 
peak within 30  min and then gradually decreased. The mean VCM concentration in 
PN rats was consistently higher than that in control rats after intraduodenal adminis-
tration. The pharmacokinetic parameters of VCM are shown in Additional file 1: Table 
S2. After intravenous administration, there were no significant differences in any of the 
pharmacokinetic parameters between the control and PN rats; however, after intraduo-
denal administration, the AUC in PN rats was approximately 2.6-fold higher than that in 
Fig. 1 Plasma concentration profiles of VCM after intravenous administration (5 mg/kg) to (open circles) 
control and (filled triangles) PN rats. Each symbol with a bar represents the mean ± SE of 4 rats
Fig. 2 Plasma concentration profiles of VCM after intraduodenal administration (20 mg/kg) to (open circles) 
control and (filled triangles) PN rats. Each symbol with a bar represents the mean ± SE of 4 rats
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control rats, with no other significant differences in the other pharmacokinetic param-
eters except for CLtot/F. The calculated bioavailability (F) of VCM in the control and PN 
rats was approximately 0.5 and 1.3 %, respectively; the F of VCN in PN rats was approxi-
mately 2.6-fold higher than in control rats.
Discussion and conclusions
The present study investigated the effect of long-term PN on VCM absorption. In 
order to more adequately induce intestinal atrophy, the period of PN administration 
was prolonged by 2  days compared with our previously reported method (Fukushima 
et al. 2015). The changes in body weight and laboratory test results in the present PN 
rats were similar to those previously reported, except for no obvious hepatic and renal 
impairment (Additional file 1: Table S1). Therefore, although no visual inspection of the 
intestines was performed in the present study, intestinal atrophy was very likely induced 
in the PN rats of the present study.
After intravenous administration, there were no significant differences in VCM phar-
macokinetic parameters, including AUC, between the control and PN rats (Fig. 1; Addi-
tional file  1: Table S2). Because most of the VCM after intravenous administration is 
eliminated from the kidneys non-metabolized, not only kidney function but also the 
binding rate of VCM to plasma proteins may have significant effects on VCM distribu-
tion. However, the present results indicated that the decrease in plasma protein observed 
in PN rats did not significantly affect the distribution and elimination of VCM, possibly 
due to the relatively low protein binding rate of VCM, which was reported to be approxi-
mately 47 % (Kusama et al. 1998). Additionally, there was no obvious renal impairment 
observed in PN rats (Additional file  1: Table S1). Therefore, PN administration in the 
present study did not alter the distribution and elimination of VCM.
After intraduodenal administration, the Cmax and AUC of VCM were increased in PN 
rats, and the bioavailability (F) of VCM showed a 2.6-fold increase in PN rats (Addi-
tional file 1: Table S2). Generally, a hydrophilic drug such as VCM is absorbed from the 
intestines via a paracellular pathway, which is modulated by tight junctions (Del Vecchio 
et  al. 2012; Prasad et  al. 2003). We previously reported the loss of intestinal epithelial 
integrity with decreases in total wet weight, mucosal protein content, and villous height 
of the intestines in rats administered PN for 7  days (Fukushima et  al. 2015), and Sun 
et  al. (2008) also reported a decrease in expression of tight junction proteins, such as 
occluding, zonula occludens and claudin, in PN-administered mice. Although the details 
of the mechanism underlying these observations still remain unclear, growing evidence 
indicates that long-term PN administration induces the disintegration of tight junctions 
along with intestinal atrophy (Feng et al. 2012; Yang et al. 2009). In addition, the slight 
hypoproteinemia and marked hypotriglyceridemia were induced by the present PN 
regimen (Additional file 1: Table S2), possibly due to the long-term treatment without 
lipid emulsion. Combined with the results of the present study, the enhanced oral bio-
availability of VCM may have been due to the disruption of tight junctions caused by 
malnutrition.
The enhanced oral bioavailability of VCM by long-term PN administration was sta-
tistically, but not clinically, significant; the VCM bioavailability of 1.3  % (Additional 
file 1: Table S2) in the present PN rats would be negligible in clinical settings. However, 
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it should be noted here that the PN rats in this study were relatively “healthy” and free 
from any complications such as renal impairment, colitis, and bacterial translocation 
(BT). Systemic exposure of VCM may be further enhanced with these complications, 
particularly in BT, in which bacteria and/or its toxins, far larger than VCM, permeate 
the intestinal mucosa. Nonetheless, the absorption of VCM itself is not necessarily an 
unfavorable feature in BT, and may possibly be utilized as a tracer for invaded bacteria. 
Therefore, the present results demonstrated that long-term PN enhances the oral bio-
availability of VCM; however, its clinical significance requires further evaluation.
In conclusion, long-term PN administration did not significantly affect the disposition 
of VCM, but increased VCM oral bioavailability, possibly due to a loss of tight junction 
integrity along with intestinal atrophy. The enhanced VCM oral bioavailability was sta-
tistically, but not clinically, significant. Therefore, while long-term PN administration 
plays a role in the enhancement of VCM bioavailability, this effect may be negligible 
without any complications.
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